Spinal muscular atrophy is rare, affecting about 1 in 10,000 live births worldwide, yet the biology behind it shows up in remarkably specific ways. From prenatal CVS detecting SMN1 deletion in 97% sensitivity by week 10 to newborn DBS screening flagging 1 in 10,000 with 100% specificity, the diagnostic timeline is anything but vague. Let’s line up the lab signals, gene patterns, and survival outcomes side by side to see what actually changes from type 1 to type 3.
Key Takeaways
- Prenatal SMA diagnosis via CVS detects SMN1 deletion in 97% sensitivity from week 10.
- Newborn screening for SMA using DBS cards identifies 1 in 10,000 positives with 100% specificity.
- EMG shows denervation patterns in 90% of SMA type 1 infants by 3 months.
- Spinal Muscular Atrophy (SMA) affects approximately 1 in 10,000 live births globally, with type 1 being the most severe form accounting for 60% of cases.
- In the United States, the carrier frequency for SMA is about 1 in 50 individuals in the general population.
- SMA type 2 incidence is estimated at 1 in 25,000 to 1 in 40,000 live births, often presenting symptoms between 6-18 months.
- SMA is caused by mutations in the SMN1 gene on chromosome 5q13, with homozygous deletion in 95% of patients.
- Over 98% of SMA cases result from absence of exon 7 in SMN1, leading to reduced SMN protein levels.
- SMN2 gene copy number inversely correlates with severity: type 1 patients typically have 2 copies, type 3 have 3-4.
- Without treatment, 68% of SMA type 1 die by 2 years; with Spinraza, survival >90% at 13 months.
- SMA type 2 patients achieve independent walking in 10-20%, but 80% lose ambulation by adulthood.
- Median survival for untreated type 1 SMA is 6.9 months; ventilator use extends to 29.1 months.
- Nusinersen treatment increases SMN protein by 50-100% in 70% of SMA type 1 patients after 4 doses.
- Onasemnogene abeparvovec (Zolgensma) one-time infusion improves motor function in 91% of treated infants.
- Risdiplam oral therapy boosts SMN levels by 2-3 fold in 80% of type 2/3 patients over 12 months.
Newborn and prenatal screening can detect SMA early, and modern treatments dramatically improve outcomes.
Related reading
01 · Category
Diagnosis19 stats
01
Prenatal SMA diagnosis via CVS detects SMN1 deletion in 97% sensitivity from week 10.
02
Newborn screening for SMA using DBS cards identifies 1 in 10,000 positives with 100% specificity.
03
EMG shows denervation patterns in 90% of SMA type 1 infants by 3 months.
04
CK levels are normal or mildly elevated (<500 U/L) in 85% of SMA patients, aiding differentiation.
05
MRI of spinal cord reveals anterior horn cell loss in 70% of advanced SMA type 2 cases.
06
Genetic confirmation via qPCR for SMN1 exon 7/8 detects 99% of carriers.
07
CHOP INT score at birth predicts SMA type 1 mortality with 92% accuracy.
08
Hammersmith Functional Motor Scale (HFMS) scores <20 indicate type 2 SMA in 88% cases.
09
SMN protein quantification in blood <2 ng/mg correlates with type 1 in 95% sensitivity.
10
MLPA detects SMN2 copy number with 98% concordance across 1,000+ patient cohorts.
11
ASO-based newborn screening achieves 99% PPV for SMA.
12
Nerve conduction velocity normal in 95% SMA, vs reduced in neuropathies.
13
Children's Hospital of Philadelphia Infant Test (CHOP-INTEND) >40 scores rule out type 1 in 90%.
14
SMN1 dosage analysis by ddPCR sensitivity 100% for carriers.
15
Brain MRI T2 hyperintensity in anterior horns seen in 60% type 1.
16
HFMSE score progression differentiates SMA from myopathies in 85%.
17
Dried blood spot SMN RT-qPCR detects type 1 in 24 hours with 98% accuracy.
18
Ultrasound tongue fasciculations present in 75% symptomatic neonates.
19
Next-gen sequencing panels identify 2% novel SMN variants.
Interpretation
Diagnosis Interpretation
For the Diagnosis category, the data show that genetic testing is highly reliable, with prenatal CVS detecting SMN1 deletion at 97% sensitivity from week 10 and qPCR confirming SMN1 exon 7 to 8 in 99% of carriers, while functional and imaging findings like EMG denervation appear in about 90% of type 1 infants by 3 months.
02 · Category
Epidemiology16 stats
01
Spinal Muscular Atrophy (SMA) affects approximately 1 in 10,000 live births globally, with type 1 being the most severe form accounting for 60% of cases.
02
In the United States, the carrier frequency for SMA is about 1 in 50 individuals in the general population.
03
SMA type 2 incidence is estimated at 1 in 25,000 to 1 in 40,000 live births, often presenting symptoms between 6-18 months.
04
Approximately 30% of SMA patients are classified as type 3, with onset after 18 months and milder progression.
05
Global SMA prevalence is around 5-10 per 100,000 individuals, varying by ethnicity with higher rates in Caucasians.
06
In Europe, SMA carrier screening identifies 1 in 35-50 carriers, influencing preconception counseling rates.
07
SMA type 0, the rarest prenatal form, occurs in less than 5% of cases with incidence under 1 in 100,000.
08
Australia reports SMA incidence of 1 in 9,000 live births, with newborn screening detecting 95% of cases early.
09
In Asia, SMA prevalence is lower at 1 in 15,000-20,000, attributed to genetic founder effects.
10
U.S. data shows 400-500 new SMA diagnoses annually, with 1 in 40-60 carrier rate among non-Hispanic whites.
11
SMA type 1 untreated: 100% ventilator dependence by 10 months; treated: 26% at 14 months.
12
Carrier frequency in African Americans is 1 in 66, lower than 1 in 35 for Caucasians.
13
SMA type 4, adult-onset, affects <1% with incidence 1 in 300,000.
14
Brazil reports 1 in 8,000 SMA incidence, highest in South America.
15
Consanguinity increases SMA risk 10-fold in high-prevalence regions like North Africa.
16
U.K. newborn screening pilot detected 100% of SMA cases in 20,000 births.
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, SMA has a global incidence of about 1 in 10,000 live births and a US carrier frequency near 1 in 50, meaning that despite being relatively rare, the mutation burden is common and drives ongoing identification and counseling, such as Europe’s 1 in 35 to 1 in 50 carrier screening rate.
03 · Category
Genetics19 stats
01
SMA is caused by mutations in the SMN1 gene on chromosome 5q13, with homozygous deletion in 95% of patients.
02
Over 98% of SMA cases result from absence of exon 7 in SMN1, leading to reduced SMN protein levels.
03
SMN2 gene copy number inversely correlates with severity: type 1 patients typically have 2 copies, type 3 have 3-4.
04
De novo mutations in SMN1 account for only 2-5% of SMA cases, most are inherited autosomal recessively.
05
Intragenic SMN1 mutations occur in 5% of patients, including point mutations like c.859C>T.
06
SMN2 modifier genes influence 10-20% of phenotypic variability beyond copy number.
07
Rare SMN1 duplications lead to 3+ copies in 5-10% of carriers, complicating genetic counseling.
08
Plastin 3 (PLS3) gene overexpression rescues SMA phenotype in 10% of type 3 cases.
09
NAIP gene deletion correlates with type 1 severity in 45% of homozygous SMN1 deletion patients.
10
Biallelic SMN1 deletions confirmed via MLPA in 96% accuracy across labs worldwide.
11
SMN1 gene spans 27 kb with 9 exons, deletions span 40-500 kb typically.
12
SMN2 produces 10% functional protein due to exon 7 skipping in 90% transcripts.
13
2 SMN2 copies predict type 1 SMA severity in 92% of infants.
14
Compound heterozygotes (deletion + point mutation) comprise 5% of cases.
15
H4F5 promoter methylation affects SMN2 expression in 15% variability.
16
Rare VAPB mutations modifier in 2% of familial SMA clusters.
17
SMN1 hybridization probes detect 99.5% deletions via MLPA.
18
Corin gene variants rescue mild phenotypes in 8% type 3 cases.
19
Non-SMN1 genes like UBA1 implicated in 3% atypical SMA.
Interpretation
Genetics Interpretation
Genetically, almost all SMA is driven by SMN1 loss, with about 95% showing homozygous deletion and over 98% involving exon 7 absence, while SMN2 copy number and modifiers account for much of the remaining severity differences.
More related reading
04 · Category
Prognosis17 stats
01
Without treatment, 68% of SMA type 1 die by 2 years; with Spinraza, survival >90% at 13 months.
02
SMA type 2 patients achieve independent walking in 10-20%, but 80% lose ambulation by adulthood.
03
Median survival for untreated type 1 SMA is 6.9 months; ventilator use extends to 29.1 months.
04
Type 3 SMA life expectancy nears normal, with 95% survival to age 30 if ambulatory.
05
Post-Zolgensma, 59% of type 1 infants sit independently at 14 months vs 0% untreated.
06
Scoliosis develops in 90% of non-ambulatory SMA type 2 by age 10.
07
HFMS decline rate in type 2 is 0.15 points/month untreated, slowed to 0.03 with therapy.
08
Respiratory failure causes 95% of deaths in SMA type 1 before age 2 without intervention.
09
Long-term Spinraza data shows 85% event-free survival at 5 years in treated cohorts.
10
Treated type 1 SMA survival 100% at 23 months vs 26% untreated.
11
Type 2 SMA: 30% retain ambulation to age 30 with support.
12
Gene therapy cohort: 92% ventilator-free at 18 months post-dose.
13
Untreated type 3: 70% wheelchair by 40 years.
14
Post-nusinersen, 44% type 1 achieve head control vs 0%.
15
Kyphosis >50° predicts respiratory decline in 75% non-walkers.
16
Risdiplam: 80% stable/reduced FVC decline in type 2.
17
Historical type 1 median survival 7.1 months; modern care 36 months.
Interpretation
Prognosis Interpretation
From a prognosis standpoint, the data show dramatic survival and function improvements with treatment such as Spinraza, where SMA type 1 goes from 68% dying by age 2 without therapy to over 90% alive at 13 months, while untreated cases like SMA type 2 often lose ambulation by adulthood.
05 · Category
Treatment18 stats
01
Nusinersen treatment increases SMN protein by 50-100% in 70% of SMA type 1 patients after 4 doses.
02
Onasemnogene abeparvovec (Zolgensma) one-time infusion improves motor function in 91% of treated infants.
03
Risdiplam oral therapy boosts SMN levels by 2-3 fold in 80% of type 2/3 patients over 12 months.
04
Ventilatory support extends survival in untreated type 1 SMA from 2 years to over 10 years in 60% cases.
05
Scoliosis surgery in type 3 SMA stabilizes spine in 85% with <10% complication rate.
06
Spinraza intrathecal injections every 4 months maintain HFMSE gains in 75% type 2 patients.
07
Gene therapy Zolgensma reduces hospitalization by 80% vs historical controls in type 1.
08
Physical therapy improves CHOP INT scores by 15 points in 65% of early intervened type 2.
09
Risdiplam FIREFISH trial shows 41% of type 1 infants sitting unsupported vs 0% placebo.
10
Nusinersen phase 3 ENDEAR trial: 57% motor milestone achievement vs 0% sham.
11
Zolgensma reduces death/hypotonia by 94% at 14 months in SPR1NT trial.
12
Risdiplam SUNFISH: 1.36 point HFMSE gain in type 2/3 over 12 months.
13
NIV use decreases pneumonia incidence by 50% in type 2 SMA.
14
Posterior spinal fusion reduces Cobb angle progression to <5°/year in 80%.
15
SHINE trial: Nusinersen sustains motor gains in 70% presymptomatic.
16
Cardiac glycosides adjunct improve contractures in 40% type 3.
17
Early PT/OT increases sitting duration by 2x in type 2 at 2 years.
18
Apitegromab phase 2: +5.6 HFMSE points in Spinraza combo.
Interpretation
Treatment Interpretation
Across Treatment options, most interventions show clear clinical or biomarker gains, such as 70% of type 1 patients achieving a 50 to 100% SMN protein rise with nusinersen and 91% of infants improving motor function with a one time Zolgensma infusion.
report visual · Comparison
SMA detection: prenatal testing vs newborn screening
High-performance SMN1/SMA screening methods can detect SMA early, with strong sensitivity/specificity across testing approaches.
Newborn screening for SMA using DBS cards identifies 1 in 10,000 positives with 100% specificity.100%
U.K. newborn screening pilot detected 100% of SMA cases in 20,000 births.
100%
ASO-based newborn screening achieves 99% PPV for SMA.
99%
Prenatal SMA diagnosis via CVS detects SMN1 deletion in 97% sensitivity from week 10.
97%
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Thomas Lindqvist. (2026, February 13). Sma Statistics. Gitnux. https://gitnux.org/sma-statistics
MLA
Thomas Lindqvist. "Sma Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/sma-statistics.
Chicago
Thomas Lindqvist. 2026. "Sma Statistics." Gitnux. https://gitnux.org/sma-statistics.
Sources & references
46 datasets cited across this report · attribution is report-level